<DOC>
	<DOC>NCT01315431</DOC>
	<brief_summary>This study is being performed to confirm the safety of tesetaxel 27 mg/m2 (Day 1) in combination with capecitabine 2000/mg/m2/day (in 2 equally divided doses on Days 1 through 14) in a 21-day cycle.</brief_summary>
	<brief_title>A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<criteria>At least 18 years of age Confirmed diagnosis of a solid tumor malignancy, excluding lymphoma Chemotherapyna√Øve or previously treated with not more than 1 nontaxanecontaining chemotherapy (Enrollment of patients with a history of prior taxane therapy in the adjuvant setting is allowed provided at least 6 months have passed since the conclusion of that therapy.) ECOG performance status of 0 or 1 Adequate bone marrow, hepatic, and renal function At least 3 weeks and recovery from effects of prior surgery and anticancer therapy, with resolution of any toxicity to not more than Grade 1 Brain metastasis or leptomeningeal disease Second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which patient has been diseasefree for 5 or more years) Known history of human immunodeficiency virus infection or hepatitis B or hepatitis C infection Recurrent diarrhea, defined as more than 3 episodes than is usual in any 24hour period within the 30 days prior to enrollment in this study Significant medical disease other than cancer Neuropathy at least Grade 2 Difficulty swallowing Malabsorptive disorder Need for other anticancer treatment while receiving study medication Need to continue any regularlytaken medication that is a potent inhibitor or inducer of the CYP3A pathway or Pglycoprotein activity. A washout period of at least 2 weeks is required prior to the first dose of study medication. Pregnancy or lactation History of hypersensitivity to tesetaxel, capecitabine, 5fluorouracil, or any of their components</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Solid tumor malignancy, excluding lymphoma</keyword>
</DOC>